Primoxyl 100 mg is an oil-based methenolone enanthate injectable manufactured by Kalpa Pharmaceuticals and dosed at 100 mg/mL in a 10 mL vial.
Primoxyl 100 mg is an injectable anabolic-androgenic steroid containing methenolone enanthate, a long-acting ester of the methenolone hormone. Methenolone is structurally a dihydrotestosterone (DHT) derivative with a 1-methyl group added, a modification that reduces its androgenic activity relative to its anabolic activity.
Methenolone enanthate is not currently marketed as an FDA-approved human pharmaceutical product in the United States. In non-medical bodybuilding settings, it is commonly referenced as one of the milder anabolic compounds, particularly during cutting phases where preserving lean mass while minimizing side effects is a priority.
Methenolone promotes muscle protein synthesis through androgen receptor activation. When used at supraphysiologic levels for physique or performance enhancement, the potential for adverse effects also increases and such use falls outside approved medical indications.
Primoxyl 100 mg uses MCT oil as its carrier oil, providing the oil base for the methenolone enanthate formulation.
Methenolone enanthate is a long-acting ester of methenolone, a mild DHT-derived anabolic steroid. Its low androgenic profile distinguishes it from testosterone and other more androgenic compounds.
The enanthate ester releases methenolone from the injection site gradually, producing a longer duration of activity than shorter-ester preparations such as methenolone acetate. The half-life is approximately 5–7 days, which means methenolone enanthate requires less frequent injection than the acetate variant.
Methenolone is a DHT derivative with a 1-methyl group that further reduces its androgenic activity. Unlike DHT itself, methenolone is not rapidly inactivated by 3-alpha-hydroxysteroid dehydrogenase in muscle tissue, which contributes to its anabolic properties. It does not aromatize to a significant degree.
These characteristics explain why methenolone enanthate is commonly referenced in non-medical cutting phases where a mild, non-aromatizing compound is preferred.
Methenolone enanthate releases methenolone more gradually than the acetate ester, with a half-life of approximately 5–7 days. This extended profile is why it is typically referenced as being administered once or twice weekly rather than daily.
Kalpa Pharmaceuticals offers several injectable anabolic formulations built around different compounds. The main practical distinctions between these preparations involve the compound's aromatization rate, androgenic profile, and intended use context.
For a shorter-acting methenolone preparation, Primoxyl uses the acetate ester in oral form. For users seeking a longer-acting drostanolone preparation, Masteroxyl 200 uses the enanthate ester. For a shorter-acting drostanolone option, Masteroxyl 100 uses the propionate ester.
The information below is provided for educational reference only. Methenolone enanthate is a prescription-class androgen in jurisdictions where it remains available; medical use requires appropriate diagnosis, clinical supervision and ongoing monitoring. Non-medical use falls outside approved indications.
In non-medical bodybuilding settings, methenolone enanthate is commonly referenced in the range of 200–400 mg per week, typically administered as one or two injections per week, though such use falls outside approved medical indications. Because methenolone is a mild compound, some users reference the higher end of this range for noticeable effects.
| Use Case | Common Reference Range | Injection Frequency |
|---|---|---|
| Non-medical cutting phase | 200–400 mg / week | Once or twice weekly |
| Stacking with a testosterone base | Commonly combined with a testosterone | Per cycle protocol |
| Preserving lean mass during caloric restriction | Typically lower end of range | Once or twice weekly |
In non-medical bodybuilding contexts, methenolone enanthate is frequently referenced as a secondary compound stacked alongside a testosterone base during cutting phases. Because methenolone can suppress endogenous testosterone production, a testosterone base is often included to maintain physiological testosterone levels. Kalpa offers several testosterone preparations that are commonly referenced in this context, including Testoxyl Cypionate 250 and Testoxyl Enanthate 250.
Methenolone enanthate may also be referenced alongside oral compounds such as Stanoxyl 10 or Oxandroxyl 10 during cutting phases. Cycle structure, duration and support compounds should be considered in the context of individual experience, health status and bloodwork where possible.
Methenolone enanthate does not aromatize to a significant degree, so estrogenic side effects such as gynecomastia and water retention are less of a concern than with testosterone. Methenolone is also considered to have a low androgenic profile, so androgenic side effects such as hair loss and acne are less pronounced than with more androgenic compounds.
Methenolone enanthate is not liver toxic in the way oral C17-alpha-alkylated steroids are, but cholesterol and hematocrit levels should be monitored during use. Aromatase inhibitors such as Arimixyl are generally less relevant with methenolone alone but may be referenced when stacking with aromatizable compounds.
After completing a cycle with Primoxyl 100 mg, post-cycle therapy is commonly recommended to help restore endogenous testosterone production and support hormonal recovery. Agents such as Clomixyl or Nolvaxyl are commonly referenced for this purpose.
Because methenolone enanthate has a longer half-life than the acetate ester, some users reference a waiting period between the last injection and the start of PCT. PCT protocols vary based on cycle length, compounds used and individual factors.
Dosing strategies, support compounds and recovery protocols should be adjusted based on experience level and bloodwork where possible. The information above is for educational reference and does not constitute medical advice.
Methenolone enanthate is an androgen that can affect hormonal, reproductive, cardiovascular and hematologic function. Medical use requires appropriate diagnosis, clinical supervision and ongoing monitoring.
Methenolone enanthate is not currently marketed as an FDA-approved human pharmaceutical product in the United States. Its safety and efficacy have not been established through the clinical trial process required for current FDA human pharmaceutical approval.
Use of methenolone enanthate at supraphysiologic levels for bodybuilding or performance enhancement falls outside any approved indication and can increase exposure to androgen-related adverse effects.
Higher-than-physiologic methenolone exposure can carry additional health risks. Product concentration and laboratory verification do not establish that non-medical use is safe or appropriate for an individual.
Methenolone can suppress endogenous testosterone production through negative feedback on the hypothalamic-pituitary-gonadal axis. This can lead to reduced testicular function and impaired fertility.
Although methenolone has a lower androgenic profile than testosterone, it may still contribute to androgenic side effects in predisposed individuals. Cardiovascular markers including lipid profile and blood pressure should be monitored during use.
Methenolone does not aromatize to a significant degree, so estrogenic side effects such as gynecomastia and water retention are less of a concern through the aromatization pathway. Individual response and risk vary according to health status, exposure and other factors.
Anabolic steroid use is not appropriate for everyone. Medical guidelines identify circumstances in which androgen therapy should be avoided or carefully evaluated, including known or suspected prostate or male breast cancer, elevated hematocrit, certain cardiovascular conditions, thrombophilia and near-term fertility plans.
Existing cardiovascular disease, abnormal blood counts and other medical conditions should be discussed with a qualified healthcare professional before any androgen use is considered.
Medically supervised androgen therapy typically involves follow-up assessment to evaluate treatment response, adverse effects and relevant laboratory markers. Monitoring may include testosterone concentrations, hematocrit, lipid profile, and prostate-related evaluation.
For non-medical use of Primoxyl 100 mg, such monitoring is not typically performed, which increases the risk of unrecognized adverse effects.
Keep the vial securely stored and protected from conditions that could compromise the product or container. Inspect the vial and solution before use and do not use a product that appears damaged, contaminated or otherwise abnormal.
Keep all medications and injectable products out of the reach of children. Follow the storage instructions provided with the product packaging.
Primoxyl 100 mg is supplied through the official Kalpa Pharmaceuticals distribution chain and shipped in original manufacturer packaging with discreet, privacy-focused handling.
The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details. Products are supplied through the official Kalpa Pharmaceuticals distribution chain.
To verify your Primoxyl 100 mg product, use the security code on the vial label and cross-check it on the Kalpa official site. Official Kalpa Pharmaceuticals presentation, batch-linked lab proof, and original packaging help reinforce product legitimacy and buyer confidence.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Proper storage conditions help preserve formulation stability and overall product integrity throughout shelf life.
Store at controlled room temperature (15–25°C) and protect from excessive heat, moisture, and direct light. Maintaining stable conditions helps preserve the integrity of the oily formulation.
Keep the vial in its original packaging until use. Do not freeze. Before administration, inspect the solution and avoid use if it appears cloudy, discolored, contains particulate matter, or if the vial or seal is compromised.
Keep out of reach of children. Follow proper handling and sterile injection practices when administering the product.
Answers to common questions about Primoxyl 100 mg, methenolone enanthate, release characteristics, product strength and how it compares to other preparations.
No, Primobolan (methenolone) is not an aromatase inhibitor. It is an anabolic steroid that does not aromatize to a significant degree, which means it does not convert to estrogen. However, not aromatizing is not the same as being an AI.
Aromatase inhibitors are a separate class of compounds used to manage estrogenic side effects. Primobolan does not function as an AI.
Methyltestosterone is a 17-alpha-alkylated oral form of testosterone that is distinct from methenolone, the active substance in Primoxyl 100 mg. Methyltestosterone is a different compound with a different pharmacological profile.
This FAQ is about Primoxyl 100 mg, which contains methenolone enanthate, not methyltestosterone. For questions about methyltestosterone specifically, consult a qualified healthcare professional.
In non-medical bodybuilding contexts, users sometimes reference a testosterone-to-primobolan ratio in stacked cycles. Common reference points include a 1:1 ratio (equal milligrams of each) or a 2:1 ratio (testosterone higher than primobolan).
There is no single correct ratio. Cycle structure, duration and support compounds should be considered in the context of individual experience, health status and bloodwork where possible.
Primoxyl 100 mg contains methenolone enanthate, a mild long-acting anabolic steroid. In non-medical bodybuilding settings it is commonly referenced during cutting phases for preserving lean mass while minimizing side effects, though such use falls outside approved medical indications.
Because of its longer half-life of approximately 5–7 days, methenolone enanthate is typically referenced as being administered once or twice weekly. This less frequent injection schedule distinguishes it from methenolone acetate, which requires more frequent administration.
Methenolone enanthate is a derivative of dihydrotestosterone with a 1-methyl group that reduces its androgenic activity. Once released, methenolone binds to the androgen receptor and promotes anabolism in skeletal muscle. It does not aromatize to a significant degree.
Methenolone enanthate is a longer-acting ester, so circulating methenolone rises gradually after administration. Its effects are correspondingly longer-lived between injections, though methenolone is a mild compound and results may be less dramatic than with more potent anabolics.
The time required to notice a change depends on what is being evaluated, the individual's starting hormone levels, treatment circumstances and other biological factors.
There is no single best compound for cutting. Methenolone enanthate is commonly referenced during cutting phases because it is mild and does not aromatize significantly, but it is often stacked with a testosterone base and other compounds.
Kalpa Pharmaceuticals offers several products that are commonly referenced in this context, including Cutaxyl 150 mg as a multi-compound cutting blend and Stanoxyl 10 as an oral cutting compound.
Both contain methenolone, but with different esters and forms. Primoxyl 100 mg is an injectable methenolone enanthate preparation, which is longer-acting and requires less frequent administration. Primoxyl is an oral methenolone acetate preparation, which is shorter-acting and requires daily administration.
A milligram amount cannot be classified as appropriate or excessive without considering the medical indication, individual response, laboratory results, treatment schedule and the specific product being used. In non-medical contexts, methenolone enanthate is commonly referenced in the 200–400 mg per week range.
It is also important to distinguish a dose in milligrams from a product's concentration in mg/mL. Primoxyl 100 mg is labeled at 100 mg/mL; that concentration does not by itself specify how much should be administered.
Primoxyl 100 mg is labeled at 100 mg of methenolone enanthate per mL. It is supplied in a 10 mL vial, giving 1,000 mg of total labeled methenolone enanthate content per vial.
March 30, 2021
4 weeks into the Primoxyl and the softballs on my shoulders are a lot more noticeable and defined. Down 2% body fat. Absolutely no Pip.